[Urachal Cancer: an update of current molecular findings].
Das Urachuskarzinom: Ein Update aktueller molekularer Ergebnisse.
Adenocarcinoma
Differential diagnosis
Immunohistochemistry
Urachal cancer
miRNA
Journal
Der Pathologe
ISSN: 1432-1963
Titre abrégé: Pathologe
Pays: Germany
ID NLM: 8006541
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
pubmed:
11
11
2019
medline:
11
1
2020
entrez:
10
11
2019
Statut:
ppublish
Résumé
Urachal cancer is a rare type of cancer, often following a clinically aggressive course. Due to its rarity, knowledge about its molecular background is still limited. In addition, no sufficiently reliable diagnostic markers are available. The aim of the present study is to give an overview of our recent molecular projects on urachal cancer and to connect it with current literature in the field. Three projects are introduced. The first project identified and validated diagnostic biomarkers in urachal adenocarcinomas compared to colorectal adenocarcinomas and primary adenocarcinomas of the bladder using various proteomic methods. In the second project, the most relevant differential diagnostic markers between urachal adenocarcinomas and colorectal adenocarcinomas compared to normal tissue (urachal remnants) were determined by analyzing a miRNA panel. Sequence analyses were performed in the third project. The focus was on molecular differences to colorectal adenocarcinomas and urothelial carcinomas. We detected potential biomarker candidates for the immunohistochemical differential-diagnosis and generated a miRNA-based diagnostic scoring system with a potentially high differential-diagnostic significance. The sequence analyses data confirm the molecular autonomy of the urachal adenocarcinomas compared to other entities.
Sections du résumé
BACKGROUND
BACKGROUND
Urachal cancer is a rare type of cancer, often following a clinically aggressive course. Due to its rarity, knowledge about its molecular background is still limited. In addition, no sufficiently reliable diagnostic markers are available.
OBJECTIVES
OBJECTIVE
The aim of the present study is to give an overview of our recent molecular projects on urachal cancer and to connect it with current literature in the field.
MATERIALS AND METHODS
METHODS
Three projects are introduced. The first project identified and validated diagnostic biomarkers in urachal adenocarcinomas compared to colorectal adenocarcinomas and primary adenocarcinomas of the bladder using various proteomic methods. In the second project, the most relevant differential diagnostic markers between urachal adenocarcinomas and colorectal adenocarcinomas compared to normal tissue (urachal remnants) were determined by analyzing a miRNA panel. Sequence analyses were performed in the third project. The focus was on molecular differences to colorectal adenocarcinomas and urothelial carcinomas.
RESULTS AND CONCLUSIONS
CONCLUSIONS
We detected potential biomarker candidates for the immunohistochemical differential-diagnosis and generated a miRNA-based diagnostic scoring system with a potentially high differential-diagnostic significance. The sequence analyses data confirm the molecular autonomy of the urachal adenocarcinomas compared to other entities.
Identifiants
pubmed: 31705235
doi: 10.1007/s00292-019-00689-4
pii: 10.1007/s00292-019-00689-4
doi:
Substances chimiques
Genetic Markers
0
Types de publication
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Pagination
239-243Références
Cancer. 1991 Apr 15;67(8):2165-72
pubmed: 1706216
Pathologe. 2018 Dec;39(Suppl 2):291-300
pubmed: 30470871
J Anat. 1930 Jan;64(Pt 2):170-83
pubmed: 17104266
Hum Pathol. 2015 Dec;46(12):1808-14
pubmed: 26364859
Korean J Urol. 2014 Sep;55(9):574-80
pubmed: 25237458
J Urol. 2012 Oct;188(4):1102-7
pubmed: 22901574
Eur Urol. 2016 Nov;70(5):771-775
pubmed: 27178450
Am J Surg Pathol. 2009 May;33(5):659-68
pubmed: 19252435
J Urol. 1982 Jan;127(1):40-2
pubmed: 7057501
Am J Surg Pathol. 2014 Aug;38(8):1033-45
pubmed: 25025366
Semin Oncol. 2012 Oct;39(5):619-24
pubmed: 23040259
Am J Surg Pathol. 2012 Mar;36(3):432-42
pubmed: 22301493
Cancer. 1955 Jul-Aug;8(4):741-58
pubmed: 13240656
Oncotarget. 2016 Jun 28;7(26):39293-39301
pubmed: 27283768
Cell. 2017 Oct 19;171(3):540-556.e25
pubmed: 28988769
Pathol Int. 2017 Dec;67(12):597-601
pubmed: 29047227
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Cancer. 2006 Aug 15;107(4):712-20
pubmed: 16826585
Int J Cancer. 2018 Oct 1;143(7):1764-1773
pubmed: 29672836
J Urol. 2006 Jun;175(6):2042-7; discussion 2047
pubmed: 16697798
J Urol. 1984 Jan;131(1):1-8
pubmed: 6361280
Dis Markers. 2018 Mar 12;2018:7308168
pubmed: 29721106
Adv Anat Pathol. 2016 Mar;23(2):71-83
pubmed: 26849813
Cancer. 1954 Jan;7(1):119-35
pubmed: 13126906
J Urol. 2003 Apr;169(4):1295-8
pubmed: 12629346
Urol Oncol. 2016 Sep;34(9):388-98
pubmed: 27267737